RxDoctor Payments Data

Catherine Russo, PA

Surgical · Salt Lake City, UTNPI 1144006834

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $720 of the $1,101 with a category attached, or 65.3%. 11 manufacturers reported payments, led by Medtronic at 50.2% of the total. 2025 is the largest year on record at $1,016, more than ten times the $31 reported in 2023.

$1,101in general payments, 2019–2025

Across 29 payments — averaging $37.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$553
  • Valencia Technologies Corporation$147
  • AbbVie$122
  • Sumitomo Pharma America, Inc.$75
  • Accord Healthcare, Inc.$51
  • AstraZeneca$35
  • plus $118 from 5 others

What the payments were for

  • Travel & lodging$31128%
  • Food & beverage$72065%
  • Education$716%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 75th percentile of 121 surgical providers in Utah.

See all surgical providers in Utah

Medicare billing

Part B allowed, 2024
$44,918
Medicare patients
191
Services billed
840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron35$18,707
GemtesaVibegron11$6,347
Methenamine Hippurate56$5,709
Estradiol38$2,374
Tamsulosin Hcl105$953
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$377
Finasteride23$340
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$327
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim61$326
Cephalexin20$323
Doxycycline Monohydrate13$253
Fluconazole26$198
Cefdinir13$152
Ciprofloxacin Hcl19$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$75$6,34711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 121 surgical providers in Utah.

Other surgical in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →